Health Care [ 2/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
It develops medicines to treat substance use disorders.
The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026.
Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 26 | 0.96 Increased by +134.15% | 0.66 Increased by +45.45% |
| Feb 26, 26 | 0.82 Increased by +157.13% | 0.65 Increased by +26.15% |
| Oct 30, 25 | 0.72 Increased by +2.30 K% | 0.41 Increased by +75.61% |
| Jul 31, 25 | 0.51 Increased by +15.91% | 0.25 Increased by +104.00% |
| Apr 24, 25 | 0.41 Increased by +10.81% | 0.23 Increased by +78.26% |
| Feb 20, 25 | 0.32 Decreased by -25.84% | 0.26 Increased by +22.65% |
| Oct 24, 24 | 0.03 Decreased by -91.18% | 0.31 Decreased by -90.32% |
| Jul 25, 24 | 0.44 Increased by +12.82% | 0.40 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 317.00 M Increased by +19.17% | 89.00 M Increased by +89.36% | Increased by +28.08% Increased by +58.90% |
| Dec 31, 25 | 358.00 M Increased by +19.73% | 102.00 M Increased by +72.88% | Increased by +28.49% Increased by +44.39% |
| Sep 30, 25 | 314.00 M Increased by +2.28% | 42.00 M Increased by +950.00% | Increased by +13.38% Increased by +926.59% |
| Jun 30, 25 | 302.00 M Increased by +1.00% | 18.00 M Increased by +118.56% | Increased by +5.96% Increased by +118.37% |
| Mar 31, 25 | 266.00 M Decreased by -6.34% | 47.00 M Decreased by -22.95% | Increased by +17.67% Decreased by -17.74% |
| Dec 31, 24 | 299.00 M Increased by +2.05% | 59.00 M Increased by +9.26% | Increased by +19.73% Increased by +7.07% |
| Sep 30, 24 | 307.00 M Increased by +13.28% | 4.00 M Increased by +102.96% | Increased by +1.30% Increased by +102.62% |
| Jun 30, 24 | 299.00 M Increased by +8.33% | -97.00 M Decreased by -348.72% | Decreased by -32.44% Decreased by -329.59% |